Janux Therapeutics Files 8-K on Shareholder Vote Matters
Ticker: JANX · Form: 8-K · Filed: Jun 13, 2025 · CIK: 1817713
| Field | Detail |
|---|---|
| Company | Janux Therapeutics, Inc. (JANX) |
| Form Type | 8-K |
| Filed Date | Jun 13, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-vote, corporate-governance
Related Tickers: JANX
TL;DR
Janux is calling for a shareholder vote on important company matters.
AI Summary
On June 11, 2025, Janux Therapeutics, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing, submitted on June 13, 2025, indicates that the company is seeking shareholder approval for certain corporate actions. The exact nature of these matters is not specified in the provided text, but it pertains to a vote by security holders.
Why It Matters
This filing signals that Janux Therapeutics is engaging its shareholders in key corporate decisions, which could impact the company's future direction and governance.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose any immediate financial or operational risks.
Key Players & Entities
- Janux Therapeutics, Inc. (company) — Registrant
- June 11, 2025 (date) — Date of earliest event reported
- June 13, 2025 (date) — Date of report filing
- Delaware (jurisdiction) — State of Incorporation
- 10955 Vista Sorrento Parkway, Suite 200, San Diego, California 92130 (address) — Principal Executive Offices
FAQ
What specific matters are being submitted for a vote by Janux Therapeutics' security holders?
The provided text of the 8-K filing does not specify the exact matters being submitted for a vote by security holders; it only states that such matters are being submitted.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 11, 2025.
On what date was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on June 13, 2025.
In which state is Janux Therapeutics, Inc. incorporated?
Janux Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Janux Therapeutics, Inc.?
The principal executive office address for Janux Therapeutics, Inc. is 10955 Vista Sorrento Parkway, Suite 200, San Diego, California 92130.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 13, 2025 regarding Janux Therapeutics, Inc. (JANX).